Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Clinuvel Pharmaceuticals ( (AU:CUV) ) has provided an update.
CLINUVEL announced the successful administration of SCENESSE® to a 9-year-old girl with severe erythropoietic protoporphyria (EPP), marking the youngest patient treated with the drug. This development highlights the potential for expanding SCENESSE®’s use to younger patients, pending regulatory approval, and underscores the company’s commitment to addressing unmet needs in EPP treatment. The treatment was well tolerated, with no adverse events, and has enabled the patient to resume normal activities, including attending school.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$46.35 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders. The company specializes in photomedicine and melanocortin peptides, offering innovative treatments for systemic photoprotection, assisted DNA repair, repigmentation, and acute conditions. Its lead therapy, SCENESSE®, is approved for preventing phototoxicity in adult erythropoietic protoporphyria (EPP) patients and is distributed in Europe, the USA, Israel, and Australia.
Average Trading Volume: 100,495
Technical Sentiment Signal: Sell
Current Market Cap: A$522.8M
Find detailed analytics on CUV stock on TipRanks’ Stock Analysis page.